Showing results (181-190 of 319) with videos related to
Sort By:
Pageof 32
Singapore Medical Journal|September 10, 2016
The Singapore Myeloma Study Group Consensus Guidelines for the management of patients with multiple myelomaSanjay de Mel, Yunxin Chen, Sathish Kumar Gopalakrishnan, et al.Oncogene|November 28, 2020
RAS-protein activation but not mutation status is an outcome predictor and unifying therapeutic target for high-risk acute lymphoblastic leukemiaDavid Koschut, Debleena Ray, Zhenhua Li, et al.Cancer Research|July 25, 2019
IL6 Promotes a STAT3-PRL3 Feedforward Loop via SHP2 Repression in Multiple MyelomaPhyllis S Y Chong, Jianbiao Zhou, Julia S L Lim, et al.Blood|August 23, 2019
MELK mediates the stability of EZH2 through site-specific phosphorylation in extranodal natural killer/T-cell lymphomaBoheng Li, Junli Yan, The Phyu, et al.EMBO Molecular Medicine|August 10, 2013
Oncogenic roles of PRL-3 in FLT3-ITD induced acute myeloid leukaemiaJung Eun Park, Hiu Fung Yuen, Jian Biao Zhou, et al.Leukemia & Lymphoma|December 16, 2025
Daratumumab bortezomib and dexamethasone in transplant ineligible newly diagnosed elderly myeloma patients (AMN006)-a trial by Asian Myeloma Network (NCT03695744)Melinda S Y Tan, Chandramouli Nagarajan, Melissa Ooi, et al.Oncotarget|March 1, 2012
Engineering the first chimeric antibody in targeting intracellular PRL-3 oncoprotein for cancer therapy in miceKe Guo, Jing Ping Tang, Li Jie, et al.Plos One|May 1, 2015
Functional Characterization of D9, a Novel Deazaneplanocin A (DZNep) Analog, in Targeting Acute Myeloid Leukemia (AML)Xia Jiang, Cheryl Zi Hui Lim, Zhimei Li, et al.Journal of Clinical Pathology|February 21, 2016
Coverage analysis in a targeted amplicon-based next-generation sequencing panel for myeloid neoplasmsBenedict Yan, Yongli Hu, Christopher Ng, et al.JCO Oncology Practice|October 16, 2023
Factors Affecting Patient and Caregiver Preferences for Treatment of Myeloma and Indolent LymphomaChia Jie Tan, Melinda Si Yun Tan, Chandramouli Nagarajan, et al.Pageof 32